AlphaYou
Overview
Smart money at a glance
Filings to Oct 13, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- 1 awardAwards on record
Market overview
Fundamentals Oct 13- Open
- $5.34
- 52-wk high
- $10.54
- High
- $5.40
- 52-wk low
- $1.90
- Low
- $5.03
- Prev close
- $5.35
- Mkt cap
- $7.8M
- Volume
- 6.2K
- Beta
- 1.02
- P/B
- 0.4x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -106.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CNSP filings
Are insiders buying or selling CNS Pharmaceuticals Inc (CNSP) stock?
Neither. CNS Pharmaceuticals Inc (CNSP) insiders filed no open-market purchases or sales in the 90 days to Oct 13, 2026, according to SEC Form 4 filings.
Which members of Congress have traded CNSP recently?
None. No member of Congress disclosed a CNSP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CNSP smart-money data?
This summary uses filings available on Oct 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
Insiders have been net buying.
What insiders are doing
Buys (2)
- FM
Fisher Michal
$10K
bought
- CF
Charles Faith L.
$34K
bought
How top traders are positioned
No tracked top-trader positions in CNSP right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 58.3% below what analysts expected.
Last report
Aug 12, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.24 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 12, 2026 | -$0.38 / -$0.24Alpha Vantage | -58.33% miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 14, 2026 | -$7.30 / -$5.37Alpha Vantage | -35.94% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 31, 2026 | -$10.15 / -$5.09Alpha Vantage | -99.41% miss | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 14, 2025 | -$5.76 / -$6.63Alpha Vantage | +13.12% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 14, 2025 | -$6.42 / -$9.60Alpha Vantage | +33.13% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 15, 2025 | -$1.58 / -$2.00Alpha Vantage | +21.00% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 31, 2025 | -$37.33 / -$7.33Alpha Vantage | -$30.00 miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 14, 2024 | -$150.00 / -$60.00Alpha Vantage | -150.00% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 13, 2026, in 31 days
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $8M
Valuation
- P/B0.41
Quality
- Operating margin0.0%
- ROE-106.6%
- ROA-58.0%
Growth
- Beta1.02
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
40 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace